Chief Commercial Officer Chris Chapman, who joined in Q4, said priorities include simplifying product acquisition for patients and physicians and ensuring that once a diagnosis is made, a prescription is written. He reiterated that “watchful waiting” remains the largest competitive alternative in molluscum, though management also said the presence of a competitor (ZELSUVMI, mentioned during Q&A) validates demand for active treatment.Management said the company continues to invest in co-pay assistance to sup ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDennis Ding - AnalystDev Prasad - SVP, Biotech Equity Research AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Anal ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDev Prasad - SVP, Biotech Equity Research AnalystGeorgia Bank - AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Ana ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker8Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may b ...

Summary of Verrica Pharmaceuticals FY Conference Call Company Overview - **Company**: Verrica Pharmaceuticals (NasdaqGM: VRCA) - **Product**: YCANTH, a treatment for molluscum contagiosum, a childhood disease affecting approximately 6 million children annually [3][4] Key Points and Arguments Product Value Proposition - YCANTH addresses a significant unmet need in treating molluscum contagiosum, which historically had no effective treatment options [3] - The disease typically lasts over 13 months, but YCANTH can control or clear it in 1 to 2 treatments [4] Adoption and Market Strategy - The company has seen more than double the dispensed units over the past year, indicating increased adoption [5] - Focused on improving the workflow for clinicians to access YCANTH, including expanding access points from medical to pharmacy benefits [6][7] - Implemented a maximum co-pay of $25 for commercially insured patients to enhance affordability [8][9] Targeting Clinicians - The company has refined its targeting strategy for clinicians, utilizing regional conferences and trade shows to reach previously untapped markets [11] - Sales representatives are empowered to engage with various healthcare providers, including pediatricians and dermatologists, to increase treatment adoption [12][14] Sales Force Dynamics - The sales force has been gradually expanded from 35-45 to 50 representatives, focusing on territories with proven demand [38][41] - New representatives are onboarded with existing reps to leverage established relationships, enhancing the speed of market penetration [44] Financial Performance and Projections - The consensus for YCANTH sales in 2026 is projected to be over $30 million, with expectations for continued growth as new customers are onboarded [46] - Inventory management has stabilized, aligning more closely with actual demand [48] Competitive Landscape - The company acknowledges competition from compounded cantharidin but believes YCANTH's FDA approval and quality differentiate it in the market [60][62] - The presence of competitors like Palvella (ZILZUMI) is seen as beneficial for raising awareness of the treatment options available for molluscum contagiosum [72] Pipeline Development - The company is advancing its pipeline, including a Phase III trial for common warts, which is expected to leverage the same clinician base as YCANTH [76][81] - The basal cell carcinoma program (VP-315) has shown promising results, with over 50% of lesions histologically cleared in Phase II trials [85] Future Opportunities - The company is exploring international markets, with plans to file for YCANTH in Europe, indicating potential for global expansion [88] Additional Important Insights - The company is focused on ensuring patient access and affordability while navigating the complexities of insurance coverage and pharmacy relationships [20][21] - The emphasis on clinician education and support is critical for increasing the adoption of YCANTH and ensuring positive patient outcomes [14][15][32] This summary encapsulates the key insights from the Verrica Pharmaceuticals FY conference call, highlighting the company's strategic focus on product adoption, clinician engagement, and pipeline development while addressing competitive dynamics and market opportunities.

Summary of Pelthos Therapeutics FY Conference Call Company Overview - **Company**: Pelthos Therapeutics (NYSEAM:PTHS) - **Lead Product**: Zelzuvmi (Berdazimer), a topical agent for treating molluscum contagiosum and external genital warts - **Acquisition**: Recently acquired Xepi (Ozenoxacin), a topical treatment for impetigo Key Points Payer Win and Market Access - Pelthos secured a major payer win covering approximately **20 million lives**, effective December 1, 2025, which significantly improves access for patients [2][3] - Prior to this win, only **5%** of prescriptions were processed through this plan, despite covering **20%** of the lives [2] - Currently, **30%** of Pelthos's business is Medicaid, with **70%** of lives covered without formal contracts [4] Product Development and Rights - Pelthos retains worldwide rights to Zelzuvmi and the right to develop it for external genital warts, while Ligand holds the intellectual property for other indications [6][7] - The company operates the API manufacturing for the NitroSil platform, which could serve as a revenue source if partnered with other companies [10] Clinical Efficacy and Market Need - **Molluscum contagiosum** has a high prevalence, with about **6 million new cases annually**, predominantly in children [15] - Zelzuvmi is the first FDA-approved at-home treatment, addressing a significant unmet need as **73%** of patients under 10 are untreated [16] - Clinical trials showed over **30%** of patients achieved complete clearance, with **77%** of parents reporting a clinically meaningful impact even without complete clearance [20] Competitive Landscape - The market currently has two main products: Zelzuvmi and YCANTH, with different treatment modalities [21] - Pelthos aims to position Zelzuvmi as the first-line therapy, while acknowledging that both products can coexist in the market [24] Commercial Strategy - Pelthos launched with **50 sales representatives**, targeting **8,000 healthcare providers**, and plans to expand to **64 reps** to cover all major metropolitan areas [28] - As of October, Pelthos had approximately **2,200 unique prescribers**, with a **41%** increase in prescriptions from September to October [36] Financial Metrics - The gross-to-net revenue for Q3 was **25.3%**, with expectations to rise to the high 20s for Q4 and stabilize in the mid- to high 30s for 2026 [39] - The company has a strategy to minimize out-of-pocket costs for patients, aiming for zero out-of-pocket payments for commercially insured patients [43] Acquisition of Xepi - Xepi was acquired due to its potential in treating impetigo, with about **3 million cases annually**, primarily in children [46] - The acquisition allows Pelthos to leverage its existing commercial infrastructure and target the same audience as Zelzuvmi [47] - Xepi's exclusivity runs until **early 2032**, while Zelzuvmi's exclusivity extends to **2035**, with a potential extension to **mid-2037** [52] Manufacturing and Barriers to Entry - Pelthos believes its specialized manufacturing capabilities create a barrier to entry for competitors, as the production process for its products is complex [53] Conclusion Pelthos Therapeutics is strategically positioned in the dermatological market with its innovative products, strong payer relationships, and a clear plan for growth through both organic expansion and acquisitions. The company is focused on addressing significant unmet needs in pediatric dermatology while maintaining a competitive edge through its unique manufacturing processes and product offerings.

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was reported at $14.3 million, a significant increase from a negative revenue of $1.8 million in Q3 2024 [21] - Net YCANTH revenue for Q3 2025 was $3.6 million, compared to negative $1.9 million in Q3 2024, reflecting improved demand and sales [21][22] - GAAP net loss for Q3 2025 was $0.2 million, or $0.03 per share, compared to a GAAP net loss of $22.9 million, or $4.88 per share in Q3 2024 [24] Business Line Data and Key Metrics Changes - Dispensed applicator units of YCANTH reached 14,093 in Q3 2025, representing approximately 5% sequential growth over the prior quarter [11] - Year-to-date dispensed applicator units increased to 37,642 for the nine months ended September 30, 2025, a 120% increase compared to the same period in 2024 [7] Market Data and Key Metrics Changes - The company received $18 million in cash milestone payments from Torii in 2025, with $10 million received in Q3 upon approval of YCANTH for molluscum in Japan [8] - Positive feedback from the European Medicines Agency indicated no further phase 3 studies are needed for YCANTH's approval for molluscum in the EU, with a filing anticipated in Q4 2026 [9][10] Company Strategy and Development Direction - The company aims to establish YCANTH as a leading therapy for multiple skin lesions, expanding beyond dermatology into pediatric and primary care [7][10] - The development of VP-315 for basal cell carcinoma is positioned as a potential standard of care, with plans for a phase 3 study design confirmed by the FDA [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of YCANTH and the potential for VP-315, highlighting a strong foundation for future growth [4][26] - The company is focused on optimizing its cost structure while advancing its clinical programs, with expectations for continued organic growth into 2026 [19][26] Other Important Information - The company has expanded its sales force to 45 representatives, with plans to increase to 50 in 2026 [15] - A new non-dispensing pharmacy, YCANTH Rx, is expected to launch in Q4 2025 to streamline prescription processes for healthcare providers [14][15] Q&A Session Summary Question: Can you further speak to the YCANTH demand that you're seeing in Q4? - Management noted that momentum from September has continued into Q4, with expectations for increased demand as the cold and flu season approaches [31] Question: What kind of counter-detailing are you seeing, and what has been the prescriber feedback on Zelsuvmi? - Management indicated that the largest competitor remains the "watch and wait" approach, but the launch of Zelsuvmi has positively influenced the market by promoting the need for treatment [32] Question: When do you expect sales force productivity to fully ramp? - Management expects new sales representatives to become productive in early 2026, as it typically takes a few months for new hires to ramp up [36] Question: Why is there a 12-month timeline for the EU filing despite no additional clinical trials required? - Management explained that the timeline includes necessary sequential steps, such as securing a pediatric waiver, which adds time to the process [38] Question: What feedback has been received regarding YCANTH Rx? - Feedback has been positive, with the new pharmacy model expected to simplify the prescription process for clinicians and improve patient access [45] Question: How should we think about seasonality impact in Q4 sales? - Management anticipates traditional slowdowns in November and December due to holidays but expects momentum to continue into early next year [50]

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was reported at $14.3 million, a significant increase from a negative revenue of $1.8 million in Q3 2024 [21] - Net YCANTH revenue for Q3 2025 was $3.6 million, compared to negative $1.9 million in Q3 2024, reflecting improved demand and sales [21][22] - GAAP net loss for Q3 2025 was $0.2 million, or $0.03 per share, compared to a GAAP net loss of $22.9 million, or $4.88 per share in Q3 2024 [24] Business Line Data and Key Metrics Changes - Dispensed applicator units of YCANTH reached 14,093 in Q3 2025, representing a 5% sequential growth from the previous quarter [11] - Year-to-date dispensed applicator units increased to 37,642 for the nine months ended September 30, 2025, a 120% increase compared to the same period in 2024 [7] Market Data and Key Metrics Changes - The company received $18 million in cash milestone payments from Torii in 2025, with $10 million received in Q3 upon approval of YCANTH for molluscum in Japan [8] - Positive feedback from the European Medicines Agency indicated no further phase III studies are needed for YCANTH's approval for molluscum in the EU, with a filing anticipated in Q4 2026 [9][10] Company Strategy and Development Direction - The company aims to establish YCANTH as a leading therapy for multiple skin lesions, expanding its use beyond dermatology into pediatric and primary care [7][10] - The development of VP-315 for basal cell carcinoma is positioned as a potential standard of care, with plans for a phase III study design confirmed by the FDA [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of YCANTH, citing a strong foundation for future growth and the potential for multiple approvals across major pharmaceutical markets [4][9] - The company is focused on maintaining a highly efficient operating model while exploring strategic partnerships to advance its pipeline [26][19] Other Important Information - The company plans to launch YCANTH Rx, a non-dispensing pharmacy, in Q4 2025 to streamline the prescription process for healthcare providers [15] - The sales force has expanded to 45 representatives, with plans to increase to 50 in 2026 [15] Q&A Session Summary Question: Can you further speak to the YCANTH demand that you're seeing in Q4? - Management noted that momentum from September has continued into Q4, with expectations of increased demand [31] Question: What kind of counter-detailing are you seeing, and what has been the prescriber feedback on Zilretc? - Management views the Zilretc launch positively, as it raises awareness about the need to treat molluscum, while YCANTH remains a best-in-class option [32] Question: When do you expect sales force productivity to fully ramp? - Management indicated that new sales representatives typically take a few months to ramp up, with expectations for productivity to increase in early 2026 [36] Question: Why is there a 12-month timeline for the EU filing despite no additional clinical trials required? - Management explained that sequential steps, including securing a pediatric waiver, are necessary for the EU filing, which adds time to the process [38] Question: What feedback have you received regarding YCANTH RX? - Feedback has been positive, with the new pharmacy model expected to simplify the prescription process for clinicians and patients [45] Question: How should we think about seasonality impact in Q4 sales? - Management expects traditional slowdowns in November and December but anticipates increased doctor visits in the cold and flu season could boost diagnoses of molluscum [50]

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $14.3 million, a significant increase from negative revenue of $1.8 million in Q3 2024 [18] - Net YCANTH revenue for Q3 2025 was $3.6 million, compared to negative $1.9 million in Q3 2024, reflecting improved demand and sales [18][19] - GAAP net loss for Q3 2025 was $0.2 million, or $0.03 per share, compared to a GAAP net loss of $22.9 million, or $4.88 per share in Q3 2024 [21] - Non-GAAP net income for Q3 2025 was $1.2 million, or $0.13 per share, compared to a net loss of $20.2 million, or $4.30 per share in Q3 2024 [21] Business Line Data and Key Metrics Changes - Dispensed applicator units of YCANTH reached 14,093 in Q3 2025, representing approximately 5% sequential growth over the prior quarter [10] - Year-to-date dispensed applicator units increased to 37,642 for the nine months ended September 30, 2025, a 120% increase compared to the same period in 2024 [6] Market Data and Key Metrics Changes - The approval of YCANTH in Japan for molluscum is expected to lead to multiple approvals across major pharmaceutical markets, including the EU [8] - Feedback from the European Medicines Agency indicated no further phase III studies are needed for YCANTH's approval for molluscum, with a filing anticipated as early as Q4 2026 [8] Company Strategy and Development Direction - The company aims to establish YCANTH as a leading therapy for multiple types of skin lesions, leveraging its existing clinician relationships [6] - The development of VP-315 for basal cell carcinoma is positioned as a potential standard of care, with plans for a phase III study design confirmed by the FDA [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of YCANTH and the potential for VP-315, highlighting a strong foundation for future growth [4][17] - The company is focused on optimizing its cost structure while expanding its commercial strategy, which has led to reduced spending and increased product adoption [5][20] Other Important Information - The company received $18 million in cash milestone payments from Torii in 2025, with $10 million received in Q3 upon YCANTH's approval in Japan [7] - A new non-dispensing pharmacy, YCANTH Rx, is expected to launch in Q4 2025 to streamline the prescription process for healthcare providers [12][13] Q&A Session Summary Question: Can you further speak to the YCANTH demand that you're seeing in Q4? - Management noted that momentum from September has continued into Q4, with expectations for increased demand as the cold and flu season approaches [24][25] Question: What kind of counter-detailing are you seeing, and what has been the prescriber feedback on Zilretc? - Management views the Zilretc launch positively, as it raises awareness about the need to treat molluscum, while YCANTH remains a best-in-class option [25] Question: When do you expect sales force productivity to fully ramp? - It typically takes a few months for new sales representatives to become fully productive, with expectations for many to be effective early in 2026 [26][27] Question: Why is there a 12-month timeline for the EU filing despite no additional clinical trials required? - The timeline includes necessary sequential steps, such as securing a pediatric waiver, which adds time to the process [27][28] Question: What feedback has been received regarding YCANTH Rx? - Feedback has been positive, with the new pharmacy model expected to simplify the prescription process for clinicians and patients [29][30] Question: How should we think about seasonality impact in Q4 sales? - Traditional seasonal slowdowns are expected in November and December, but increased doctor visits during the cold and flu season may boost diagnoses of molluscum [32][33]

Group 1 - Verrica Pharmaceuticals held its Q1 2025 Corporate Update Conference Call on May 13, 2025, with key participants including the CEO, CFO, and COO [1][3] - The call included discussions on the commercialization of YCANTH for treating molluscum contagiosum in the U.S., revenue growth, regulatory developments, and the company's product candidates [4][5] - Management emphasized the importance of forward-looking statements regarding the company's business strategy and operations, highlighting potential risks and uncertainties [4][5]